2026年7月18日-24日，全球医药市场共签署了24项资产授权和合作协议。中国市场共达成6项交易，包括1项引进交易、1项出海交易和4项国内交易。
国内市场上，本周最大的国内交易是同源康医药与齐鲁制药就已申报上市资产asandeutertinib达成在中国大陆区域的许可与合作及供应和商业化协议，首付款4200万美元，总金额可达3.84亿美元。
国际市场上，本周共签署了18项资产授权和合作协议。最大的交易是Royalty Pharma从Neurimmune手中收购阿斯利康临床三期资产cliramidut的部分特许权权益，首付款1.25亿美元，总金额可达4.25亿美元。
From July 18 to 24, a total of 24 agreements were signed worldwide. Within China’s biotech industry, there was one in-licensing deal, one out-licensing deal and four domestic transactions.
In China, the largest deal involved TYK medicines and Qilu Pharmaceutical for the filed asset asandeutertinib, with an upfront payment of $42million and a total deal value of $384 million.
Globally, 18 deals were announced. The largest deal involved Royalty Pharma and Neurimmune for AstraZeneca's Phase III asset cliramitug, with an upfront payment of $125 million and a total deal value of up to $425 million.
3. Top Deals of 2026
